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Abstract: Ranolazine blocks the intracellular sodium and calcium overload accompanying myocardial ischemia and
is used in antianginal therapy. The effects of ranolazine on the β-adrenoceptor signal transduction system are poorly
understood. The present study was designed to confirm whether the mechanism was associated with a β-adrenocep-
tor antagonist activity of ranolazine on norepinephrine (NE)-induced cardiomyocytes. After cardiomyocytes were
preincubated with propranolol and ranolazine, cells were treated with NE for 24 hours. The phosphorylation of ERK
was decreased by ranolazine treatment, in comparison with NE-only treated cells. Intracellular Ca2+and Na+ levels
decreased by 40±3% and 17±0.5%, respectively, compared to control. Ranolazine decreased expression of Ca2+/
calmodulin-dependent protein kinase II (CaMKII) by 57±4%, the Na+-Ca2+exchanger (NCX) by 21±0.5%, and the
ryanodine receptor 2 (RyR2) by 47±1.5%, compared with NE-only treated control cells. Ranolazine also increased
expression of the L-type Ca2+channel (LTCC) by 48±3.5%, phospholamban (PLB) levels by 45±2%, and the sarco-
plasmic reticulum Ca2+ATPase 2a (SERCA2a) by 36±0.5%, compared to levels in NE-only stimulated cells. The
number of annexin V/PI-positive cells fell by 39±1.5% after ranolazine treatment, compared with levels in NE-only
treated control cells. Ranolazine also inhibited apoptosis by regulating the levels of the pro-apoptotic factor Bax, the
anti-apoptotic factor Bcl-2, and cytochrome C release. These results demonstrate that ranolazine had an effect on
NE-induced cell death through inhibition of the β-adrenoceptor signal pathway in cardiomyocytes.
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1. Introduction







 Ranolazine has been shown to
block the late sodium current in ischemic cardiomyocytes.
Therefore, ranolazine is thought to indirectly reduce
Ca
2+
overload via an action on Na
+
 channels, preserving ionic
homeostasis.
2
 Acute intravenous administration of ranolazine
improved left ventricular systolic function in animal models of
heart failure.
3
 However, the sodium current inhibitor
mechanism of ranolazine has not been defined.
4
 The actions of
norepinephrine (NE) involve binding to adrenergic receptors.
5,6
NE, a β-adrenoceptor agonist, plays a role in many
cardiovascular diseases including congestive heart failure.
Also, NE has a co-mitogenic effect in isolated cardiac
fibroblasts, and activates mitogen-activated protein kinases
(MAPKs).
7
 The MAPKs, a large family of serine-threonine
kinases, play important roles as mediators of signal
transduction and are activated by extracellular stimuli.
8,9
 Three
subgroups of MAPKs have been clearly identified; these are the
extracellular signal-regulated kinases (ERK1/2), the p38
kinase, and the c-jun N-terminal kinases (JNKs). ERK1/2
responds to mitogenic stimuli, whereas p38 kinase and JNKs
respond predominantly to cellular stresses or inflammatory
cytokines.
9,10
 Recently, heterotrimeric G proteins have also
been shown to activate various members of the MAPK
family.
8,9
 One of the major mechanisms for regulating
contractility of the heart involves β-adrenoceptor stimulation.
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The β-adrenoceptor is the first element in the signal
transduction chain mediating adrenergic stimulation of the
heart. All known subtypes of the β-adrenoceptor (β1, β2, and β3)
are glycoproteins with extracellular amino-termini, seven
hydrophobic transmembrane domains, and intracellular
carboxy-termini. All three subtypes, when activated, can cause
increases in intracellular levels of cAMP, although many recent
studies have demonstrated that this is not the sole signaling
pathway.
11,12
 Selective agonists and antagonists exist for all
three receptor subtypes.
13
 The β-adrenoceptor antagonists are
used therapeutically for treatment of cardiovascular diseases
such as cardiac failure, angina, and hypertension, and the
beneficial effects result mainly from action on the heart.
14
Regardless of the underlying mechanism, systemic β-
adrenoceptor antagonists can have a number of significant
effects on cardiac function.
15
As a second messenger, Ca
2+
 regulates acute physiological
functions, including contraction of cardiac, skeletal, and
smooth  musc les ,  and re lease  of  hormones  and
neurotransmitters. Variations in Ca
2+
 homeostasis can lead not
only to loss of normal physiological control mechanisms but
also to pathological changes in cell growth. Cardiac dilatation
and pump dysfunction without intrinsic myocardial systolic
failure follows chronic β-adrenoreceptor activation.16 Increases
in Ca
2+
 levels can transduce signals through various classes of
Ca
2+
-regulated enzymes, one of which is the Ca
2+
/calmodulin-





dependent protein kinase II (CaMKII) is a widely expressed
protein kinase that modulates various functions including
learning and memory in the nervous system, muscle
contraction, cell secretion, and gene expression.
17
 In the heart,
CaMKIId is the predominant CaMKII isoform and a splice
variant thereof, dc, resides in the cytosol. In addition to a well-
documented role in regulation of cardiac excitation-contraction
(E-C) coupling,18-20 CaMKIIdc has been implicated in
apoptotic signaling21-24 and in mediating the transition to heart
failure.25 CaMKII regulates an array of key proteins involved in
cardiac E-C coupling and Ca2+ processing, such as the
sarcoplasmic/endoplasmic reticulum Ca2+ATPase (SERCA)
and regulators thereof, for example phospholamban (PLB) and
the ryanodine receptor (RyR) Ca2+ release channels.20,21,25
A β-adrenoceptor stimulus increases apoptosis26 and the
levels of reactive oxygen species (ROS)27 in cardiomyocytes.
ROS, generated by a variety of extracellular and intracellular
mechanisms, have gained attention as novel signal mediators
that regulate signal transduction events and are known to play
important roles in the pathogenesis of several cardiovascular
diseases. ROS are recognized to regulate the transcription of
particular genes.
28
 However, ROS may specifically induce
apoptosis.
29
 Recent work has demonstrated that chronic
adrenergic stress is associated with adverse effects, such as
cardiac failure, mainly because of increased cardiomyocyte
apoptosis.
30
 Apoptosis has been demonstrated to occur in the
myocardium in a variety of pathological situations.
31
 The
number of apoptotic myocytes is increased in myocardium
obtained from patients with end-stage heart failure and
myocardial infarction,
32
 and in myocardium from experimental
models of myocardial hypertrophy and failure, including the
rat,
33
 the spontaneously hypertensive rat,
34
 and rats with
myocardial infarction.
35
 Many molecules, including proteins in
the Bcl-2 and caspase families, participate in the apoptotic
response to numerous death-inducing signals.
36
We therefore sought to confirm whether ranolazine exerted
an antagonist activity at the β-adrenoceptor level in
norepinephrine (NE)-induced cardiomyocytes. The β-
adrenoreceptor antagonist propranolol can blunt the
cardiomyocyte hypertrophic response in the heart. Propranolol
has other pharmacological effects, such as a Na
+
 channel-
blocking action and an antioxidant effect.
37
 In the present study,
it was expected that ranolazine would have an effect similar to
that of propranolol in NE-induced cardiomyocytes. Because





 overload, and Ca
2+
 channel (LTCC, NCX,
SERCA2a,  PLB,  and RyR2)  gene  express ion in
cardiomyocytes, we tested whether ranolazine inhibited






 channel gene expression in NE-induced
cardiomyocytes. The mechanisms of NE-induced ROS
expression, and apoptosis, were examined in cardiomyocytes
and it was found that NE-induced apoptosis was accompanied
by downregulation of Bcl-2 protein synthesis and activation of
β-adrenergic and cytochrome C release mechanisms.
2. Materials and Methods
2.1 Isolation and Culture of Rat Cardiomyocytes
Neonatal rat cardiomyocytes were prepared by an enzymatic
method. Briefly, hearts of 1-2-day-old Sprague-Dawley (SD)
rat pups were dissected, minced, enzymatically dispersed in 10
mL of collagenase II solution (0.5 mg/mL, 262 U/mg, Gibco
BRL, Paisley, UK), and differentially centrifuged to yield
5×105 cells/mL. After incubation for 2 h, cells were rinsed
twice in a-MEM (Gibco) containing 10% (v/v) fetal bovine
serum (FBS) (Gibco), and 0.1 M BrdU (Sigma Chemical Co.,
St. Louis, MO) was added to inhibit fibrous cell growth. Cells
were next cultured in a CO2 incubator at 37
oC for 1 day.
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2.2 NE Stimulation and Treatment with Propranolol
and Ranolazine
Cardiomyocytes were incubated in 5% (v/v) CO2 at 37
o
C for
1 day. The cells were next placed into a-MEM without FBS in
a CO2 incubator (Thermo Forma Model 311, Marietta, USA)
for 24 h. Cells were then pre-incubated with propranolol
(2 µM), or ranolazine (3 µM), or a mixture of propranolol and
ranolazine, and exposed to NE (10 µM) for 24 h.
2.3 Measurement of Intracellular Sodium Level by
Flow Cytometry
Intracellular sodium was measured by the Corona green
method (CoroNa™ Green AM, Molecular Probes, Eugene,
OR, USA). Cells (5×10
6
) were cultured for 1 day on a plate 100
mm in diameter coated with 1.5% (w/v) gelatin. For
intracellular sodium measurement, Corona green stock solution
was added to 1 mL of cells to yield a final concentration of
5 µM stain, at 1 h prior to assay. Incubation was continued at
37
o
C under a 5% (v/v) CO2 atmosphere. Before flow
cytometric examination, propidium iodide (PI) (Sigma) was
added to a final concentration of 10 µg/mL. Cells (1×104) were
analyzed by sequential excitation at 492-516 nm and 488 nm,
respectively, using a FACSCalibur system (Becton Dickinson,
San Jose, CA), and Cell Quest™ software for evaluation
purposes. 
2.4 Measurement of Intracellular Reactive Oxygen
Species Generation
Neonatal rat cardiomyocytes were labeled with 2’7’-
dichlorodihydro-fluorescein diacetate (H2DCFDA; Molecular
Probes). The probe (10 µM) enters the cell, and the acetate
group on H2DCFDA is cleaved by cellular esterases, thus
trapping nonfluorescent 2’7’-dichlorodihydro-fluorescein
(DCFH) internally. Subsequent oxidation by ROS yields the
fluorescent product DCF. The dye, when exposed to an
excitation wavelength of 480 nm, emits light at 535 nm only
after oxidization. Labeled cells were examined by
luminescence spectrophotometry.
2.5  Confocal  Microscopy and Fluorescence
Measurements
Cytosolic free Ca2+concentration was estimated by confocal
microscopy. Neonatal rat cardiomyocytes were plated in a four-
well slide chamber coated with 1.5% (w/v) gelatin for 1 day in
a-MEM containing 10% (v/v) FBS and 0.1 µM BrdU. After
incubation, cells were washed with modified Tyrode’s solution
containing 0.265 g/L CaCl2, 0.214 g/L MgCl2, 0.2 g/L KCl,
8.0 g/L NaCl, 1.0 g/L glucose, 0.05 g/L NaH2PO4, and 1.0 g/L
NaHCO3. Cells were next loaded with 10 µM of the
acetoxymethylester of fluo-4 (Fluo-4 AM, Molecular Probes)
for 20 min, in the dark at 37
o
C. Images were collected using a
confocal microscope (Leica, Solms, Germany) by excitation
with the 488 nm line of an argon laser, and emitted light was
collected through a 510-560 nm bandpass filter. Relative levels
of intracellular Ca
2+
were determined by measuring
fluorescence intensity .
2.6 Annexin V/PI Staining
Apoptosis was measured using an ApoScan™ Annexin V-
FITC apoptosis detection kit (Biobud, Seoul, Korea). Cells
were pelleted and analyzed in the FACSCalibur system. The
excitation frequency was 488 nm. The green fluorescence
emitted by Annexin V (FL1) and the red fluorescence of PI
(FL2) were measured using 525 nm and 575 nm bandpass
filters, respectively. A total of at least 1×10
4
 cells was analyzed
in each sample. Light scattering was measured on a linear scale
using 1,024 channels and the fluorescence intensity was
assessed on a logarithmic scale. The levels of early apoptosis











Drug-treated cells were washed once in PBS and lysed in a
lysis buffer (Cell Signaling, Beverly, MA) containing 20 mM
Tris (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA,
1% (v/v) Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
β-glycerophosphate, 1 mM Na3VO4, 1 mg/mL leupeptin, and 1
mM PMSF. The protein concentration in each fraction was
determined using a BCA protein assay kit (Pierce
Biotechnology, Rockford, IL). Proteins were separated in 10-
15% (w/v) SDS-polyacrylamide gels and electrotransferred to
methanol-treated polyvinylidene difluoride membranes
(Millipore Co, Bedford, MA). After blocking the membrane
with Tris-buffered saline-Tween 20 (TBS-T containing 0.1%
[v/v] Tween 20) and 10% (w/v) skim milk for 1 h at room
temperature, each membrane was washed twice with TBS-T
and incubated with antibodies against ERK1 (Santa Cruz
Biotechnology, Santa Cruz, CA), phospho-ERK1/2 (Santa
Cruz Biotechnology), anti-cytochrome C (Santa Cruz
Biotechnology), Bcl2 (Santa Cruz Biotechnology), and Bax
(Stressgen Biotechnologies, Victoria, BC, Canada) for 1 h at
room temperature or overnight at 4oC. Each membrane was
washed three times with TBS-T for 5 min on each occasion, and
next incubated for 1 h at room temperature with appropriate
horseradish peroxidase (HRP)-conjugated secondary
antibodies. After extensive washing, bands were detected using
The effect of Ranolazine on Inhibition of the β-adrenoceptor
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an enhanced chemiluminescence (ECL) reagent (Amersham
Pharmacia Biotech, Piscataway, NJ). Band intensities were
quantified using a Photo-Image System (Molecular Dynamics,
Uppsala, Sweden).
2.8 RT-PCR Analysis
2.8.1 Isolation of Total RNA
Total RNA was extracted using 500 µL/60 mm-diameter
plate of TRIzol (Sigma). Chloroform (100 µL) was added to the
extract and each sample was vortexed for about 10 sec. Next,
centrifugation at 12,000 g, at 4
o
C for 15 min, caused three
layers to appear, and the transparent upper layer was collected
in a new tube. Each sample next received 250 µL 2-propanol,
and vortexing for about 30 sec was repeated. Centrifugation at
12,000 g, at 4
o
C for 10 min, followed. The supernatant was
discarded and the pellet washed in 75% (v/v) ethanol admixed
with diethylpyrocarbonate (DEPC; Sigma), and dissolved in
water. Centrifugation at about 7,500 g, at 4
o
C for 5 min,
followed. The supernatant was again discarded and the pellet
dried at room temperature for about 7 min. Finally, each pellet
was dissolved in 30 µL nuclease-free water (NFW). The
quality and quantity of RNA were estimated by calculation of
OD260/OD280 ratios using a DU 640 spectrophotometer
(Eppendorf, Hamburg, Germany).
2.8.2 cDNA Synthesis
Complementary DNA (cDNA) was synthesized using the
RT&GO™ kit. One microgram of RNA was added to 1 µL of
the anchored primer dT 25V, 2 µL dithiothreitol (DTT), and
NFW, to yield a final volume of 9 µL. To prevent development
of secondary structure, the mixture was incubated for 5 min at
70
o
C and 8 µL RT-&GO™ mastermix was next added. Each
sample was incubated at 42
o
C for 1 h. Next, reverse
transcriptase was added and incubation continued at 70
o
C for
15 min. As described above after isolation of total RNA,
sample quality and quantity were estimated by calculation of
OD260/OD280 ratios.
2.8.3 PCR Analysis
One microgram of cDNA, and 10 pmol of each primer
(forward and backward; Table 1), 0.1 mM of a dNTP mixture,
1.25 U Taq polymerase, and 10 X reaction buffer were mixed
with NFW to give a final volume of 25 µL. PCR conditions
were as follows. A cycle of denaturation at 94
o
C for 3 min was
followed by 35 elongation cycles each featuring denaturation at
94
o
C for 30 sec, annealing at 48-60
o
C for 30 sec, and elongation
at 72
o
C for 30 sec. The reaction was next held at 72
o
C for
10 min. Primers used are shown in Table 1. PCR products were
separated by electrophoresis in 1.2% (w/v) agarose gels
(Biorad, Seoul, Korea) and Gel-Doc (Biorad) was used to
visualize bands after staining with ethidium bromide (Sigma).
2.9 Statistical Analysis
Data from three individual experiments are expressed as
means±SEs. Statistical analysis was performed using one-way
ANOVA, employing the Bonferroni test for between-group
comparisons. A P value <0.05 was considered significant.
3. Results
3.1 Ranolazine Inhibited Phosphorylation of ERK in
NE-Induced Cardiomyocytes
Table 1. PCR primers used in this study
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NE stimulation increased MAPK/ERK activation in
cardiomyocytes. Therefore, we explored the effect of
ranolazine after NE stimulation. Although phosphorylation of
ERK increased by 63±1% after treatment with NE for 24 h,
ERK phosphorylation fell by 52±2.5% after ranolazine
treatment (Fig. 1), compared with the level seen in NE-induced
cardiomyocytes. 
3.2 Ranolazine Decreased CaMKII Overexpression in
NE-Induced Cardiomyocytes
During NE stimulation, CaMKII expression was increased.
Therefore, we examined the CaMKII expression level in NE-
induced cardiomyocytes using RT-PCR. The level of CaMKII
increased by 73±2% in NE-induced cardiomyocytes. After
treatment of NE-induced cells with ranolazine, the level of
CaMKII fell by 57±4% compared with that in NE-induced
cardiomyocytes (Fig. 2). 




We examined cardiomyocytes at the single-cell level for
changes in intracellular sodium concentration using the
fluorescent Corona green (Na+) dye test and flow cytometry.
With gating for only normal-sized or positive control cells, NE
treatment in the presence of Corona green (Na+) resulted in a
rise of 21±2% in cells in the M1 stage, compared with control
cells and those treated with propranolol, ranolazine, or a
mixture of ranolazine and propranolol, where reductions of
18±3%, 17±0.5%, and 17±2.5%, respectively, in M1 cells were
noted, compared to the level in NE-induced cardiomyocytes
(Fig. 3). 
3.4 Ranolazine Prevented Intracellular Ca
2+
Accumulation after NE Stimulation
Intracellular Ca
2+
 level was increased by activation of several
Ca
2+
 channels in NE-induced cardiomyocytes. As shown in
Fig. 4, the intracellular Ca
2+
 level during NE stimulus was
elevated by 50±3% at 24 h but fell by 43±0.5%, 40±3%, and
50±1.5% after treatment of cells with 2 µM propranolol, 3 µM
ranolazine, and a mixture of propranolol and ranolazine,
respectively. 




Ca2+ entry through the L-type Ca2+ channel (LTCC) into
cardiomyocytes is known to be the initiating event of the E-C
coupling process. LTCC are critically involved in excitation/
secretion coupling whereby membrane depolarization activates
the LTCC. The density of LTCC was diminished by 63±2%
after NE stimulation compared with that of control cells. After
NE-induced cells were treated with ranolazine, the density of
LTCC was elevated by 48±3.5% in comparison with NE-
stimulated cells (Fig. 5). 




We examined the expression of Ca2+ channels related to
Figure 1. Phosphorylation of ERK in NE-induced cardiomyo-
cytes. Relative phosphorylation levels of ERK activity were
determined by western blotting. Cardiomyocytes were subjected
to NE stimulation with propranonol and ranolazine for 24 hr.
phosphorylation of ERK was treated during NE stimulation was
detected by immunoblotting. Values are mean±SEM.
Figure 2. CaMKII expression in NE-induced cardiomyocytes.
Cardiomyocytes treated with ranolazine and propranolol were
exposed to NE stimulation for 24 hr. Whereas NE treated cells
were increased in CaMKII mRNA, ranolazine treated cells were
completely decreased in CaMKII mRNA. Values are
mean±SEM.




 regulation, which is important in cell
function, and sought changes in expression levels of one of the
representative Ca
2+
 channels, NCX1, and Ca
2+
 control within
cells, involving SERCA2a and regulators thereof, including
PLB and RyR2. Tests were conducted on cardiomyocytes
exposed to NE. RyR2 and NCX gene expression levels in NE-
induced cardiomyocytes treated with ranolazine were reduced
by 47±1.5% and 21±0.5%, respectively, compared to levels in
NE-treated cells (Fig. 6A). The expression levels of SERCA2a
and PLB were higher, by 36±0.5% and 45±2%, respectively,
than levels in NE-induced cells (Fig. 6B). These results showed
that ranolazine prevented changes in SERCA2a, PLB, NCX,
and RyR2 expression levels.
3.7 Ranolazine Decreased Reactive Oxygen Species
Production in NE-Induced Cardiomyocytes
ROS, including hydrogen peroxide (H2O2) and hydroxyl
radicals, are normally generated in mitochondria and are
important mediators of signal transduction.37,38 Significant
enhancement in fluorescence intensity was detected in NE-
treated cells after 24 h of culture, compared to levels in control
cells (Fig. 7A). ROS production was increased by 71±0.5%
after NE (10 µM) treatment of cardiomyocytes for 24 h (Fig.
7B). Although ROS production in ranolazine- treated cells
decreased by 52±1.5% with respect to the level in NE-exposed
cells, ROS production in propanolol-treated cells fell more than
did ROS synthesis in ranolazine-treated cells. 
3.8 Ranolazine Prevented NE-Induced Apoptosis of
Cardiomyocytes
The level of apoptosis, as measured by the proportion of
Annexin V-positive cardiomyocytes, was investigated after
exposure of cells to NE with or without propranolol and
ranolazine (Fig. 8). The number of Annexin V-positive
cardiomyocytes fell by 39±1.5% after ranolazine treatment,
compared with the level seen in NE-treated cells. In contrast,
Figure 4. Effects of ranolazine on intracellular Ca2+ concentra-
tion. Confocal fluorescent images of cardiomyocytes were
obtained by loading with fluo-4 AM. The NE-induced cells
treated with ranolazine and propranolol were incubated for 24 hr.
(A) Fluorescence image was obtained by fluo-4 AM and (B) flu-
orescence intensity was quantified in different cells (n=5) in each
condition and analyzed. Values are mean±SEM.
Figure 5. L-type Ca2+ channel expression level in NE-induced
cardiomyocytes. Cardiomyocytes treated with ranolazine and
propranolol wasexposed to NE stimulation for 24 hr. The mRNA
expression of genes was established by separating amplification
products in agarose gel electrophoresis and visualized them by
ethidium bromide staining. Each expression was quantified by
scanning densitometer. Values are mean±SEM.
Figure 3. Effects of ranolazine on intracellular Na+ overload in
NE-induced cardiomyocytes. NE treatment in the presence and
absence of ranolazine was initially examined for changes in intra-
cellular sodium by flow cytometry using corona green (Na+). The
cells were initially analyzed by gating on only the normal cell or
NE treated cells on a side scatter histogram plot. Subsequently,
this population of cells was then analyzed on a corona green
(Na+) fluorescence histogram. An increase in corona green (Na+)
fluorescence indicates an increase in intracellular sodium. Only
the NE treated cells increased in intracellular sodium, indicating
Na+ overload. Values are mean±SEM. 
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propranolol showed no such effect. 
3.9 Ranolazine Inhibited Apoptosis by Regulation of
levels of the Pro-Apoptotic Factor Bax and the Anti-
Apoptotic Factor Bcl-2, in NE-Induced Cardiomyocytes
NE induced cytochrome C release from mitochondria to the
cytosolic fraction. Although cytochrome C was released into
the cytosol from the mitochondrial intermembrane space
during NE stimulation, treatment of cells with ranolazine
during NE stimulus blocked cytochrome C release into the
cytosol (Fig. 9A). A notable attenuation of Bcl-2 protein
expression and a remarkable enhancement of Bax expression
occurred in NE-induced cardiomyocytes, but ranolazine-
treated cells did not exhibit evident changes in the expression of
either Bax or Bcl-2 (Fig. 9B-C).
4. Discussion
In the present study, we showed that ranolazine decreased
cell death mediated by the β-adrenoceptor signaling pathway in
NE-induced cardiomyocytes. Also, it was demonstrated that
ranolazine inhibited Ca2+ and Na+ cell overload, and influenced
the levels of intracellular Ca2+-regulatory proteins after NE
stimulation. Ultimately, ranolazine inhibited apoptosis of
cardiomyocytes.
NE activates the MAPK signaling pathway. To determine
whether ranolazine treatment of NE-induced cells affected
MAPK signaling pathway activity, we explored ERK protein
phosphorylation using Western blotting. Although
phosphorylation of ERK was elevated by NE exposure for 24
Figure 7. Reactive oxygen species (ROS) production. After prein-
cubated with propranolol (2 µM), ranolazine (3 µM), mixture of
propranolol and ranolazine in cardiomyocytes, it was treatedwith
10 µM NE for 24 hr. (A) Fluorescence image and (B) fluores-
cence intensity was obtained by using DCF fluorescence. Value
are mean±SEM.
Figure 6. Effects of ranolazine on Ca2+ channel levels in NE-induced cardiomyocytes. Expression levels of the RyR2, NCX1, SERCA2a
and PLB were estimated in cardiomyocytes subjected to NE with or without ranolazine, propranolol and analyzed. Values are
mean±SEM.
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h, phosphorylation fell after ranolazine treatment, to a level
lower than that shown after exposure to NE (Fig. 1).
Mann and colleagues have suggested that NE exerts a direct
toxic effect on cardiomyocytes in vitro.
40
 β-adrenoceptor





 calmodulin-dependent protein kinase II
(CaMKII) activity.
41,42
 CaMKII is the major cardiac isoform.
Also, CaMKII expression was increased by β-adrenoceptor
stimulation.
43
 To confirm that CaMKII expression was
enhanced by β-adrenoceptor stimulation, we examined
CaMKII gene expression in NE-induced cardiomyocytes. The
gene expression level was confirmed to be affected by
ranolazine treatment of NE-induced cardiomyocytes. Whereas
NE treatment enhanced CaMKII mRNA levels, ranolazine
treatment completely inhibited mRNA transcription from the
gene encoding CaMKII (Fig. 2). 
Stefan and co-workers showed that CaMKII regulated Na
+
channel function in cardiomyocytes, most likely by association









 To test for Na
+
 overload, we examined
cardiomyocytes at the single-cell level for changes in
intracellular Na
+
 concentration using the fluorescent Corona
green (Na
+
) dye test coupled with flow cytometry. With gating
for only normal-sized or positive control cells, NE treatment in
the presence of Corona green (Na
+
) resulted in an increase in
the proportion of cells in the M1 stage, compared with normal
control cells. Also, treatment of cells with propranolol,
ranolazine, or both ranolazine and propranolol, reduced the cell
proportion in M1 compared with that of NE-induced
cardiomyocytes (Fig. 3). The stimulation of β-adrenoceptor





 concentrations in cardiomyocytes. 
Ca
2+
 is arguably the most important second messenger in
cardiac muscle. Changes in intracellular Ca
2+
concentration
have both acute and chronic effects on cardiac function.
42
 β-
adrenergic modulation of voltage-sensitive Ca
2+
 channels in
myocardial cells initiates a slow inward current, carried mainly
by Ca
2+
, that profoundly influences cardiac function.
44
 It has
been observed that intracellular Ca
2+
 overload increased in NE-
induced cardiomyocytes and fell after treatment with
ranolazine, propranolol, or both materials in combination (Fig.
4). Ca
2+
 ions play an important role in normal cardiac function,
Figure 9. Bcl-2/Bax ratio and cytochrome C release. Cardiomyocytes were exposed to NE for 24 hr with propranolol, ranolazine and
mixture of ranolazine and propranolol. (A) Mitochondria/ Cytosolic cytochrome C and the (B) Bcl-2/Bax protein ratio were detected by
western blotting and (C) densitometric analysis. Values are mean±SEM. *p<0.001 vs. Control. #p<0.05 vs. NE.
Figure 8. Annexin V/PI staining in apoptosis analysis. Cardiomy-
ocytes were exposed to NE for 24 hr with propranolol, ranolazine
and mixture of ranolazine and propranolol. Effect of ranolazine
and propranolol in NE-induced apoptosis was detected by the
annexin V-PI staining assay using flow cytometry. Values are
mean±SEM.




-regulating proteins are associated with Ca
2+
homeostasis in cardiomyocytes. β-adrenoceptor stimulation by
sympathetic NE plays a pivotal role in modulation of cardiac
function in response to stress. Previous studies have shown that
the ATP-induced increase in [Ca
2+
] is potentiated by NE. This
increase in the ATP response mediated by NE has been
demonstrated to be attributable to Ca
2+
 entry through the
sarcolemmal (SL) LTCC. In this regard, it has been emphasized
that NE has been shown to phosphorylate the LTCC and to
enhance the inward Ca
2+
 influx. Major Ca
2+
-cycling proteins
involved in LTCC action are RyRs, SERCA2a, NCX, and PLB.
The LTCC provides the primary Ca
2+
 influx mechanism and





disparities in the levels of expression of LTCC in NE-induced
cardiomyocytes have been noted. The expression level of
LTCC was increased after NE stimulation, compared with
control cells. After treatment of NE-induced cells with
ranolazine, the level of LTCC expression increased further (Fig.
5). SERCA plays an important role in regulating cytoplasmic
Ca
2+
 levels in cardiomyocytes and is the most important
contributor to the lowering of Ca
2+
 levels during cardiac
relaxation.
16





 may contribute to the diminished contractile function
occurring in animal models of heart disease and in humans with
severe congestive heart failure. NCX and RyR2 expression
levels were increased by β-adrenoceptor stimulation.48 We
showed that NCX and RyR2 expression levels were elevated in
NE-induced cardiomyocytes and that ranolazine blocked these
changes (Fig. 6A). The expression levels of SERCA2a and
PLB were reduced in NE-induced cardiomyocytes but were
enhanced by treatment with ranolazine (Fig. 6B).
Many studies have shown that NE induces apoptosis in vitro
and in vivo.
44
 NE can induce ROS generation and apoptosis of
cardiomyocytes by activation of the β-adrenergic pathway.45
Regardless of the underlying mechanisms, an enhanced ß-
adrenoceptor stimulation may significantly contribute to
chronic diseases, such as hypertension and related conditions,
congestive heart failure, sudden cardiac death, insulin-
resistance syndrome, and obesity.49 A significant increase in
fluorescence intensity was detected in cells treated with NE for
24 h, as compared to both control groups. This was clearly
caused by increased oxidative stress in NE-induced
cardiomyocytes. Oxidative stress diminished after treatment
with ranolazine. However, ROS production in propranolol-
treated cells decreased more than did ROS production in
ranolazine-treated cells (Fig. 7). 
Apoptosis is triggered when something is amiss in the cell.
DNA damage, cell detachment from neighbors, growth factor
deprivation, infection, and a host of other triggers, have been
described. In the present study, ranolazine was used to examine
the mechanisms of NE-induced apoptosis in cardiomyocytes. It
was found that NE-induced apoptosis was accompanied by
downregulation of Bcl-2 protein synthesis and activation of
Bax. NE-induced apoptosis was detected by Annexin V/PI
staining (Fig. 8). Very little apoptosis was detected in control
cultured cardiomyocytes, but cells underwent significant
apoptosis when exposed to NE. Pretreatment with ranolazine,
or co-treatment with ranolazine and propranolol, significantly
reduced the apoptosis rate. In contrast, propranolol alone had no
such effect. Cytochrome C plays a central role in apoptosis,
signaling the cell to commence the process of cell death.
Cytochrome C release from mitochondria has also been
observed during NE-induced apoptosis (Fig. 9A). The anti-
apoptotic protein Bcl-2 plays an important role in controlling
cell death. It has been observed that NE-treated cardiomyocytes
showed lower Bcl-2 protein levels, whereas the Bax protein
level was increased. However, ranolazine-treated cells were
protected against NE stimulation (Fig. 9B). These results are in
agreement with previous reports showing that Bcl-2 acts
upstream of the caspase cascade. Notably, if the rise in
intracellular Na
+
 is prevented using ranolazine, a complete
inhibition of apoptosis is observed. Thus, a rise in intracellular
Na
+
 appears to act in initial signaling of the apoptotic program. 
5. Conclusion
This study suggests that ranolazine is involved in β-
adrenoceptor activation and prevents NE-induced apoptosis. In
NE-treated cardiomyocytes, phosphorylation of ERK was
inhibited in ranolazine-treated cells compared with cells treated
with NE alone. Ranolazine also reduced intracellular Ca
2+
 and
Na+ levels by regulating CaMKII expression after NE
stimulation and affected Ca2+ channel-related gene expression.
Although ranolazine had only a minor influence on NE-
induced ROS production, the drug had a protective effect on
apoptosis occurring after NE stimulus. In NE-treated
cardiomyocytes, ranolazine diminished apoptotic protein
expression levels in comparison with NE-only-treated cells.
Ranolazine may thus act on the β-adrenoceptor signaling
pathway to prevent NE-mediated cardiomyocyte apoptosis
during heart failure.
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